Moleculin Biotech, Inc. 8-K

What Happened

• Moleculin Biotech, Inc. (MBRX) filed a Form 8-K on January 13, 2026 (Item 7.01) disclosing a press release announcing that an independent assessment confirmed no cardiotoxicity associated with its drug candidate Annamycin in 90 subjects. The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Independent assessment outcome: no cardiotoxicity observed in 90 subjects.
• Filing date / disclosure: Form 8-K filed January 13, 2026 under Regulation FD (Item 7.01).
• Press release attached as Exhibit 99.1; filing also includes standard Exhibit cover (Inline XBRL).

Why It Matters

• Cardiac safety is a common regulatory and investor concern for oncology drugs; an independent assessment reporting no cardiotoxicity in 90 subjects addresses a key safety risk for Annamycin.
• This disclosure is a company announcement of safety assessment results; it does not include new financial guidance or other operational changes. Investors should view it as a clinical/safety update that could affect development risk perceptions but should rely on future company releases and regulatory filings for further clinical data and implications.